PROTAC BRD4-binding moiety 4, identified by its CAS number 2126819-55-2, is a chemical compound that plays a significant role in targeted protein degradation, particularly in the context of cancer research. This compound is part of a class of molecules known as PROTACs (Proteolysis Targeting Chimeras), which are designed to harness the cell's ubiquitin-proteasome system to selectively degrade specific proteins. The BRD4-binding moiety indicates that this compound specifically targets the bromodomain-containing protein 4 (BRD4), a protein implicated in various cancers and inflammatory diseases. Characteristics of this compound include its ability to engage with BRD4, facilitating the recruitment of E3 ligases that tag the protein for degradation. This mechanism offers a novel therapeutic strategy by reducing the levels of oncogenic proteins, thereby potentially inhibiting tumor growth. The compound's structure and functional groups are tailored to optimize binding affinity and selectivity for BRD4, making it a valuable tool in drug discovery and development aimed at treating diseases associated with dysregulated protein expression.

PROTAC BRD4-binding moiety 4

2126819-55-2: PROTAC BRD4-binding moiety 4, identified by its CAS number 2126819-55-2, is a chemical compound that plays a significant role in targeted protein degradation, particularly in the context of cancer research. This compound is part of a class of molecules known as PROTACs (Proteolysis Targeting Chimeras), which are designed to harness the cell's ubiquitin-proteasome system to selectively degrade specific proteins. The BRD4-binding moiety indicates that this compound specifically targets the bromodomain-containing protein 4 (BRD4), a protein implicated in various cancers and inflammatory diseases. Characteristics of this compound include its ability to engage with BRD4, facilitating the recruitment of E3 ligases that tag the protein for degradation. This mechanism offers a novel therapeutic strategy by reducing the levels of oncogenic proteins, thereby potentially inhibiting tumor growth. The compound's structure and functional groups are tailored to optimize binding affinity and selectivity for BRD4, making it a valuable tool in drug discovery and development aimed at treating diseases associated with dysregulated protein expression.

Desmethyl-QCA276, a QCA276 derivative, forms PROTAC through a linker to target cereblon, degrading BET proteins; IC50: 10 nM, Ki: 2.3 nM.

CAS 2126819-55-2

PROTAC BRD4-binding moiety 4

Desmethyl-QCA276

Ref: TM-T18601